Progress in treatment of small-cell lung cancer: role of CPT-11

N Saijo, N Saijo

Abstract

Small-cell lung cancer (SCLC) accounts for approximately 15% of all cases of lung cancer and is a particularly aggressive form of lung cancer characterised by a poor prognosis, rapid tumour growth, and early metastasis. Roughly, two-thirds of patients with SCLC present with extensive disease (ED) and one-third with limited disease (LD). Combination chemotherapy is the most effective treatment modality for SCLC, and several new agents, including carboplatin, ifosfamide, taxans, and topotecan, have been demonstrated to be active; however, there are no data on the survival benefit of these drugs. A CPT-11+ cisplatin regimen has shown improvement in overall survival over the global gold standard regimen, etoposide + cisplatin (Japanese Clinical Oncology Group: JCOG 9511), and three confirmatory randomised controlled trials are in progress to determine the reproducibility of the JCOG 9511 study. JCOG is evaluating the role of CPT-11 and a new triplet regimen containing CPT-11 in limited-stage SCLC. Strategies and the current protocols of the JCOG are presented and discussed. In the future, it will be essential to evaluate molecular target-based drugs for LD and ED SCLC with new standard combination chemotherapy regimens that include CPT-11.

Figures

Figure 1
Figure 1
Phase III Study of CPT-11/CDD vs VP-16/CDDP in SCLC (JCOG9511).
Figure 2
Figure 2
Treatment schema.
Figure 3
Figure 3
Randomised phase III trial for LD-SCLC (JCOG 02002): Ongoing.

References

    1. Devore R, Blanke C, Denham C, Hainsworth JD, Gralla RJ, Koletsky AJ, Savaraj N, Vogal CL, Sarma GP, Brooks DJ, Petit RG, Elfing GL, Schaaf LJ, Hanover CK, Miller LL (1998) Phase II study of CPT-11 in patients with previously treated small cell lung cancer. Proc Amer Soc Clin Oncol 17: 451a
    1. Elias AD, Ayash L, Frei E, Skarim AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP (1993) Intensive combined modality therapy for limited-disease small cell lung cancer. J Natl Cancer Inst 85: 559–566
    1. Evans WK, Feld R, Murray N, William A, Coy P, Osoba D, Shepherd FA, Clark DA, Levitt M, McDonald A, Wilson K, Shelley W, Pater J (1987) Superiority of alterrating cross resistant chemotherapy in extensive small cell lung cancer. A multicenter randomized clinical trial by National Cancer Institute of Canada. Ann Intern Med 107: 451–458
    1. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanwski M, Oka M, Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB506 and SN38, in human small cell lung cancer cells. Cancer Res 56: 789–793
    1. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosplamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83: 855–861
    1. Goto K, Sekine I, Nishiwaki Y, Sugiura T, Kawase I, Saijo N (2002) Phase II study of weekly cisplatin etoposide and irinotecan (PF/CPT) for relapsed small cell lung cancer. Proc Amer Soc Clin Oncol 21: 316
    1. Hanna NH, Einhorn LH (2002) Small cell lung cancer: State of the art. Clin Lung Cancer 4: 87–94
    1. Jeremic B, Shibamoto Y, Acimovi CL, Milisavljevic S (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol 15: 893–900
    1. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small cell lung cancer. Cancer Res 50: 5919–5924
    1. Karato A, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Oshita F, Nishio M, Kunikane H, Arioka H, Ohmatsu H, Nakashima H, Shiraishi J, Saijo N (1993) Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 11: 2030–2035
    1. Kelly K (2001) Irinotecan in small cell lung cancer: current data. Clin Lung Cancer 2: S4–S8
    1. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M for the West Japan Lung Cancer Group (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small cell lung cancer. J Clin Oncol 16: 1068–1074
    1. Le Chevalier T, Ibrahim N, Chomy P, Riviere A, Mannier A, Magherini E, Pujol JL (1997) A phase II study of irinotecan in patients with small cell lung cancer progressing after first line treatment. Proc Amer Soc Clin Oncol 16: 450a
    1. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Saijo N (1992) CPT-11: a new derivative of comptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10: 1225–1229
    1. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matusi K, Takifuji N, Nakagawa K, Tomonari M, Nitta T, hirashima T, Negoro S, Takada M (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777–782
    1. Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yano T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M (1998) Combination of irinotecan and etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 16: 3329–3334
    1. Mori K, Kuboka K, Nishiwaki Y, Sugiura T, Noda K, Kawahara M, Negoro S, Watanabe K, Yokoyama A, Nakamura S, Tamura T, Saijo N (2002) Cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy followed by three cycles of irinotecan and cisplatin. Proc Amer Soc Clin Oncol 21: 1173
    1. Murray N, Shah A, Osoba D, Page R, Harssi H, Graftion C, Gostard K, Fairey R, Voss N (1991) Intensive weekly chemotherapy for the treatment of extensive small cell lung cancer. J Clin Oncol 9: 1632–1638
    1. Murray N, Zee B, Coy P, Hodson I, Arnoid A, Payne D, Kostashuk E, Evans W, Dixan W, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11: 336–344
    1. Murray N, Livinggston RB, Shephard FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Craft H, Osoba D, Ottoway J, Gandara D (2001) Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: an intergroup study of NCI-Canada CTG and SWOG. J Clin Oncol 17: 2300–2308
    1. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991a) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non small cell lung cancer. J Natl Cancer Inst 83: 1164–1168
    1. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kukiyama T, Nishiwaki Y, Ogawa M, Nakao I, Saijo N, Obo K, Furue H, Ariyoshi Y, Shimokata K, Furuse K, Nakajima S, Irie K, Kimura I, Ogura T, Fujii M, Hara N, Hara Y, Nakano S, Araki J, Miyata Y, Taguchi T (1991b) A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18: 1013–1019
    1. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura K, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N for Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. Eng J Med 346: 85–91
    1. Ohe Y, Saijo N (2002) Result of recent Japanese clinical trials in lung cancer. Clin Lung Cancer 4: 243–248
    1. Perry MC, Eaton WL, Propert KJ, Ware JH, Eimmer B, Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner C (1987) Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N Engl J Med 316: 912–918
    1. Pignon JP, Aiagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoski T, Osterlind K, Tattersall MHN, Wagner H (1992) A meta—analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327: 1618–1624
    1. Saijo N (1996) Clinical trials of irinotecan hydrochoride (CPT, campto injection, tepotecin injection) in Japan. In the camptothecins from discovery to the patients. Pantazis P, Giovanella BC, Rothenberg ML (eds). Ann NY Acad Sci 803: 292–305 (The New York Academy Sciences, New York)
    1. Saijo N (2002) Preclinical and clinical trials of topoisomerase inhibitors, In ‘The Camptothecins Unfolding their Anticancer Potential’. Liehr JG, Giovanella BC, Verschraegen CF (eds). Ann NY Acad Sci 922: 92–99 (The New York Academy Sciences, New York)
    1. Saijo N (2002) Irinotecan combined with radiation therapy for patients with stage III non-small cell lung cancer. Clin Lung Cancer 4: S21–S25
    1. Sandler A (2001) Irinotecan: future directions in small cell lung cancer. Clin Lung Cancer 2: S9–S13
    1. Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y, Oshita F, Nishio M (1994) 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonylony camptothecin: mechanisms of resistance and clinical trial. Cancer Chemoher Pharmacol 34: S112–S117
    1. Sandler A (2002) Irinotecan in small cell lung cancer: Current data and the status of on going trials. Clin Lung Cancer 4: S30–S34
    1. Schulthesis CP, Raheam MA, Perry MC (2001) Second line chemotherapy for small cell lung cancer: a review. Clin Lung Cancer 3: 118–124
    1. Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, Negoro S, Yokoyama A, Matsui K, Osaki Y, Nakano T, Saijo N (2003) Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every four weeks for extensive small cell lung cancer: JCOG 9902-DI. Ann Oncol 14: 709.
    1. Shihabi S, Belani CP (2001) Role of topoisomerase I inhibitor in small cell lung cancer. Clin Lung Cancer 4: 275–281
    1. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N (2002) Phase III study of concurrent vs sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20: 3054–3060
    1. Tamura K, Takeda M, Kawase I, Tada T, Kudoh S, Okishio K, Fukuoka M, Yamaoka N, Fujiwara Y, Yamakido M (1997) Enhancement of tumor-radio response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88: 218–223
    1. Trussi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice daily compared with once daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271
    1. Work E, Nielsen O, Bentren S (1997) Randomized study of initial versus late chest irradiation combined with chemotherapy in limited stage small cell lung cancer. J Clin Oncol 15: 3030–3037
    1. Yokoyama A, Kurita Y, Saijo N, Tamura T, Noda K, Shimokata K, Matsuda Y (1998) Dose finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non small cell lung cancer. Br J Cancer 78: 257–262

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться